Renal Biomarkers Market is expected to grow at a CAGR of 9.1% during the forecasted period | Evolve Business Intelligence

Key Highlights:
• The global Renal Biomarkers Market size was valued at USD 1.5 billion in 2023 growing at a CAGR of 9.1% from 2023 to 2033.
• North America dominated the market in 2023
• Asia Pacific is expected to grow at the highest CAGR from 2023 to 2033

As per the study initiated by Evolve Business Intelligence, the global Renal Biomarkers Market size accounted for USD 1.5 Billion in 2023, growing at a CAGR of 9.1% from 2023 to 2033. Renal biomarkers are substances or indicators that can be measured in biological fluids, such as blood or urine, to assess the function and health of the kidneys. These biomarkers play a crucial role in the diagnosis, prognosis, and monitoring of various kidney-related conditions and diseases. Monitoring renal function is essential for the early detection of kidney injury, assessment of disease progression, and evaluation of treatment efficacy. Several renal biomarkers are used in clinical practice and research to evaluate kidney function and identify renal damage. Some commonly used renal biomarkers include serum creatinine, blood urea nitrogen (BUN), and estimated glomerular filtration rate (eGFR). Additionally, newer and more specific biomarkers, such as neutrophil gelatinase-associated lipocalin (NGAL), kidney injury molecule-1 (KIM-1), and cystatin C, have gained prominence in recent years for their ability to provide early and sensitive detection of kidney injury.

Request/Download PDF Sample: https://report.evolvebi.com/index.php/sample/request?referer=OpenPR&reportCode=021528

The rising prevalence of kidney diseases, including chronic kidney disease (CKD) and acute kidney injury (AKI), is a significant factor driving the demand for renal biomarkers. Early detection and monitoring of kidney diseases are crucial for effective management and treatment. The aging global population is more susceptible to kidney-related conditions. As the elderly population increases, there is a higher demand for diagnostic tools and biomarkers that can aid in the early identification of kidney dysfunction. Technological advancements in the field of diagnostics and laboratory testing have led to the development of more sensitive and specific renal biomarkers. This has improved the accuracy and reliability of kidney disease diagnosis and monitoring.

Key Players
Some of the major Renal Biomarkers Market players holding high market shares include Beckman Coulter, Inc., Thermo Fisher Scientific Inc., Abbott Laboratories, Bioporto Diagnostics A/S, and Astute Medical, Inc. These players use partnership and collaboration as a key strategy to gain significant market share to compete with market leaders. Some of the other major market players include Randox Laboratories, Sphingo Tec GmbH, Siemens Healthineers AG, Eli Lilly and Company, and Novartis AG

For More Information: https://report.evolvebi.com/index.php/sample/request?referer=OpenPR&reportCode=021528

Segmental Analysis
Based on biomarker type, the Renal Biomarkers market is segmented into Functional Biomarker, Up-Regulated Proteins, and Others. Functional biomarkers are a type of biomarker that measures the function of a particular organ or system. In the case of renal biomarkers, functional biomarkers can be used to assess the function of the kidneys. Some examples of functional renal biomarkers include creatinine, blood urea nitrogen (BUN), and glomerular filtration rate (GFR).
Based on technique, the Renal Biomarkers market is an Enzyme-Linked Immunosorbent Assay, Particle-Enhanced Turbidimetric Immunoassay, Calorimetric Assay, Chemiluminescent Enzyme Immunoassay Liquid Chromatography-Mass Spectrometry. ELISA is a type of immunoassay that is used to detect and quantify the presence of a particular substance in a sample. In the case of renal biomarkers, ELISA can be used to measure the levels of a variety of renal biomarkers, including creatinine, BUN, and KIM-1.
Based on End Use, the Renal Biomarkers market is Diagnostic Labs, Outpatient Clinics, Research Centers, and Hospitals. Diagnostic labs are facilities that are used to diagnose diseases and conditions. In the case of renal biomarkers, diagnostic labs can use a variety of tests to measure the levels of renal biomarkers, including ELISA, PETIA, and LC-MS

Key Region/ Countries Covered
• North America (US, Canada, Mexico)
• Europe (Germany, U.K., France, Italy, Spain, Russia, Nordic Countries, BeNeLux, Rest of Europe)
• Asia-Pacific (China, India, Japan, South Korea, Indonesia, Malaysia, Rest of Asia Pacific)
• Middle East and Africa (Saudi Arabia, UAE, Egypt, South Africa, Rest of MEA)
• Latin America (Mexico, Brazil, Argentina, Rest of Latin America)

Address
Evolve Business Intelligence
C-218, 2nd floor, M-Cube
Gujarat 396191
India
Email: sales@evolvebi.com
Website: https://evolvebi.com/

About EvolveBI
Evolve Business Intelligence is a market research, business intelligence, and advisory firm providing innovative solutions to challenging pain points of a business. Our market research reports include data useful to micro, small, medium, and large-scale enterprises. We provide solutions ranging from mere data collection to business advisory.
Evolve Business Intelligence is built on account of technology advancement providing highly accurate data through our in-house AI-modelled data analysis and forecast tool - EvolveBI. This tool tracks real-time data including, quarter performance, annual performance, and recent developments from Fortune's global 2000 companies.

This release was published on openPR.